"We are pleased to offer physicians and their patients a reliable, accurate and affordable asthma measurement and management device," said Rich Lotti, President and CEO of Apieron, Inc. "We believe this product will improve the standard of care for patients with asthma enabling physicians to optimize medical therapy for each patient."
"The availability of simple to use, accurate, and economically feasible eNO measurement devices now enables physicians to intelligently assess and manage the key pathologic feature of asthma, airway inflammation," said Peter B. Boggs, M.D., Clinical Professor of Pediatrics and Medicine, LSU School of Medicine, Shreveport, Louisiana. "Prior to the availability to measure eNO, assessing and managing airway inflammation was, for all practical purposes, little more than a guess! The ability to measure eNO in the physician's office is 'one giant step' in the care of adults and children with asthma."
The Insight eNO system includes a small desktop monitor with an easy-to- read display, trend analysis capabilities and a user-friendly interface. The system uses disposable, single-use sensors to measure nitric oxide accurately and non-invasively in less than a minute. Disposable, single-use breath tubes make it hygienic and convenient for the user to exhale into the device. Patient data can be stored and maintained in unique patient cards for trend analysis or downloaded to a printer for insurers' and patients' files.
About Apieron Inc.
Apieron Inc. is a private, venture-backed medical device company based
in Menlo Park, CA that was formed in early 2001 to develop a simple-to-use,
non- invasive monitor for the measurement of exhaled nitric oxide (eNO) for
the management of asthma. The Apieron biosensor technology platform
utilizes a patented technology that allows for the highly sensitive
detection of se
|SOURCE Apieron, Inc.|
Copyright©2008 PR Newswire.
All rights reserved